Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
Status:
Open
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
NCT#04739800
GY023 is nearing accrual goal and is anticipated to close to accrual, effective March 1, 2023.
